EVO100 + Placebo
Phase 3Completed 2 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sexually Transmitted Diseases
Conditions
Sexually Transmitted Diseases, Gonorrhea, Chlamydia
Trial Timeline
Oct 15, 2020 → Jul 28, 2022
NCT ID
NCT04553068About EVO100 + Placebo
EVO100 + Placebo is a phase 3 stage product being developed by Evofem Biosciences for Sexually Transmitted Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT04553068. Target conditions include Sexually Transmitted Diseases, Gonorrhea, Chlamydia.
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04553068 | Phase 3 | Completed |
| NCT03107377 | Phase 2/3 | Completed |